Changes in HRD “Fingerprints” in Patients with Ovarian Cancer and Their Impact on Clinical Outcomes

Videos

Featuring:

Amina Ahmed, MD
Associate Chief Medical Officer
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
Paula Anastasia, RN, MN, AOCN
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
Amina Ahmed, MD, and Paula Anastasia, RN, MN, AOCN, debate the need for rebiopsy and retesting of molecular biomarkers in patients with HRD-discordant responses. The experts agree that reliability of the HRD “fingerprint” is dependent on the validity of the HRD test used as well as the ability to interpret results from these tests.

Related Articles

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: